Jaguar Health

Jaguar Health, Inc. is a commercial stage pharmaceuticals company, which engages in the development of gastrointestinal products. The firm focuses on developing novel, plant-based, non-opioid, and sustainably derived prescription medicines for people and animals with GI distress, specifically chronic, debilitating diarrhea. It operates through the Human Health and Animal Health segments. The Human Health segment manufactures human products and the ongoing advertising of Mytesi, which is used for the symptomatic relief of non-infectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. The Animal Health segment commercializes prescription and non-prescription products for companion and production animals. The company was founded by Lisa A. Conte on June 6, 2013 and is headquartered in San Francisco, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Jaguar Health reports revenue growth and eyes cancer therapy market

Jaguar Health's Q1 2024 performance showed revenue growth and improved financial metrics. The company's strategic focus on cancer supportive care and rare diseases positions it for future growth. Challenges include trial result uncertainties and regulatory timelines, but opportunities exist in market expansion and new programs.

Jaguar Health reports revenue growth and promising clinical trial results

Jaguar Health's Q2 2024 earnings call showcases revenue growth, positive clinical trial outcomes, and strategic plans for product launches and FDA discussions. The company's focus on improving patient outcomes and expanding its product reach positions it for future success in the healthcare market.

Jaguar Health reports revenue growth and advances in cancer care

Jaguar Health's Q3 performance reflects revenue growth, successful trial outcomes, and a focus on cancer patient care through innovative products.
While facing challenges in regulatory processes and financial metrics, the company is well-positioned to capitalize on opportunities in rare diseases and oncology.
Overall, Jaguar Health's strategic initiatives and commitment to addressing critical medical needs position it for potential growth and impact in the healthcare sector.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Jaguar Health, Inc. is a commercial stage pharmaceuticals company, which engages in the development of gastrointestinal products. It operates through the Human Health and Animal Health segments. The Human Health segment is involved in manufacturing human products and the ongoing advertising of Mytesi, which is used for the symptomatic relief of non-infectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. The Animal Health segment includes commercializing prescription and non-prescription products for companion and production animals. The company was founded by Lisa A. Conte on June 6, 2013 and is headquartered in San Francisco, CA.

Jaguar Health, Inc. (NASDAQ:JAGX ) Q3 2024 Results Conference Call November 12, 2024 8:30 AM ET Company Participants Lisa Conte - Founder, President & Chief Executive Officer Pravin Chaturvedi - Chief Scientific Officer Carol Lizak - Chief Financial Officer Operator [Call Starts Abruptly] before I turn the call over to management, I'd like to remind you that management may make forward-looking statements relating to such matters as continued growth prospects for the company, uncertainties regarding market acceptance of products, the impact of competitive products and pricing, industry trends and product initiatives, including products in the development stage, which may not make -- achieve scientific objectives or meet changing regulatory requirements. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from those complicated in such forward-looking statements.

Jaguar Health, Inc. (JAGX) Q3 2024 Earnings Call Transcript

The combined net Q3 2024 revenue of approximately $3.1 million for prescription and non-prescription products, including license revenue, increased approximately 14% versus net Q2 2024 revenue of $2.7 million and 11% versus net Q3 2023 revenue of $2.8 million Jaguar reported significant results in breast cancer patients in its phase 3 OnTarget trial for its cancer supportive care drug crofelemer; results in breast cancer patients accepted for poster presentation on December 11, 2024 at the San Antonio Breast Cancer Symposium (SABCS) Jaguar initiated commercial launch in October 2024 for Gelclair ®, the company's third prescription product, in alignment with Jaguar's focus on cancer supportive care Jaguar is initiating two Phase 2 trials in Q4, 2024 and supporting multiple investigator-initiated proof-of-concept studies ("IIT") of crofelemer for the rare and orphan disease indications of microvillus inclusion disease (MVID) and short bowel syndrome (SBS) with intestinal failure in the US, EU, and Middle East/North Africa (MENA) regions; results of IITs expected by the end of 2024 and throughout 2025 REMINDER: Jaguar to host investor webcast Wednesday, November 13th at 8:30 a.m. Eastern regarding Q3 2024 financials and company updates; Click here to register for webcast SAN FRANCISCO, CA / ACCESSWIRE / November 13, 2024 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") today reported its consolidated third-quarter 2024 financial results and provided Company updates.

Jaguar Health Reports Third Quarter 2024 Financial Results

Click here to register for investor webcast Company plans to file its Earnings Report on November 13, 2024 on Form 10-Q for the quarter ended September 30, 2024 SAN FRANCISCO, CA / ACCESSWIRE / November 11, 2024 / Jaguar Health, Inc. (NASDAQ:JAGX) today announced that the company will conduct an investor webcast on Wednesday, November 13, 2024 at 8:30 a.m. Eastern to review third-quarter 2024 financials and provide corporate updates.

Jaguar Health to Hold Investor Webcast Wednesday, November 13th at 8:30 AM Eastern Regarding Q3 2024 Financials & Corporate Updates

Canalevia®-CA1 is the first and only treatment for chemotherapy-induced diarrhea (CID) in dogs to receive any type of approval from the FDA By prescription only, Canalevia-CA1 is a canine-specific formulation of crofelemer, Jaguar's novel, oral plant-based product sustainably harvested from the Croton lechleri tree SAN FRANCISCO, CA / ACCESSWIRE / November 6, 2024 / Jaguar Health, Inc. (NASDAQ:JAGX), under its Jaguar Animal Health tradename for the veterinary market, today announced that the U.S. Food and Drug Administration (FDA) has approved renewal of Canalevia-CA1 (crofelemer delayed-release tablets). Canalevia-CA1, the company's conditionally approved prescription drug for the treatment of chemotherapy-induced diarrhea (CID) in dogs, is available from multiple leading veterinary distributors in the U.S., including Chewy.

FDA Approves Renewal of Canalevia-CA1, Jaguar Health's Drug for Chemotherapy-Induced Diarrhea in Dogs

Adult patients with breast cancer are a prespecified subgroup of the recently conducted OnTarget trial evaluating crofelemer for prophylaxis of cancer therapy-related diarrhea (CTD) A second late-breaking abstract related to the OnTarget trial, based on data from the placebo arm of the study, has also been accepted for a poster presentation at SABCS SAN FRANCISCO, CA / ACCESSWIRE / November 4, 2024 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar") family company Napo Pharmaceuticals ("Napo") today announced that the late-breaking abstract about the recently completed analysis of the prespecified subgroup of adult patients with breast cancer from the Phase 3 OnTarget trial, which indicates that crofelemer achieved significant results in this subgroup, has been accepted for a poster presentation on December 11, 2024 at the San Antonio Breast Cancer Symposium (SABCS). Patients with breast cancer accounted for the majority of participants in this unprecedented prophylactic clinical trial recently conducted by Napo for diarrhea in adult patients with solid tumors receiving targeted therapy with or without standard chemotherapy.

Abstract Describing Significant Results of Crofelemer for Cancer Therapy-Related Diarrhea in Breast Cancer Patients Accepted for Presentation at San Antonio Breast Cancer Symposium (SABCS)

It is estimated that 10-15% of people in the United States have IBS SAN FRANCISCO, CA / ACCESSWIRE / October 29, 2024 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar") family company Napo Pharmaceuticals ("Napo") today announced that the abstracts are now available for two independent investigator-initiated studies of crofelemer, Napo's novel, plant-based oral prescription drug, that show a benefit in patients with chronic refractory diarrhea and are the subject of poster presentations taking place today, October 29, 2024, at the American College of Gastroenterology Annual Scientific Meeting (ACG 2024) in Philadelphia, Pennsylvania. Descriptions of both studies appear below, along with a link to the virtual ACG 2024 ePoster Hall page for each study - which display the poster for each study and provide a short audio presentation of the posters.

Significant Positive Results with Jaguar Health's Crofelemer for Chronic Refractory Diarrhea in IBS-D, Presented at American College of Gastroenterology Annual Meeting

The stock of small-cap biotech Jaguar Health Inc. rose 7% on Wednesday, after the company launched its gelclair treatment for oral mucositis, a common side effect suffered by head and neck cancer patients.

Small-cap biotech Jaguar Health's stock jumps 7% as it launches treatment for oral mucositis in cancer patients

Gelclair ® is the company's third commercialized prescription product Oral mucositis, also called "chemo mouth," a painful inflammation of the mouth's mucous membranes, has emerged as the most significant adverse event in oncology according to a National Comprehensive Cancer Network task force Severe mucositis/pharyngitis occurred in 70% of head and neck cancer patients in third-party study SAN FRANCISCO, CA / ACCESSWIRE / October 16, 2024 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar") today announced that Jaguar family company Napo Pharmaceuticals ("Napo") has initiated the commercial launch of the FDA-approved oral mucositis prescription product Gelclair in the U.S. "Cancer is chaotic, because patients feel a loss of control - over their life, their treatment, and their supportive care needs," said Catherine Collis, Jaguar's Senior Vice President of Growth Strategy. "Jaguar's mission is to change patients' lives for the better, especially in the area of supportive care for complex disease states like cancer.

Jaguar Health Launches FDA-Approved Oral Mucositis Prescription Product Gelclair in the U.S.

SAN FRANCISCO, CA / ACCESSWIRE / October 11, 2024 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") today announced that, effective October 7, 2024, the Company granted 80,000 restricted stock units (RSUs) to New Employee 1 and 15,000 RSUs to each of four other new employees ("New Employees 2-5"). The RSUs for New Employee 1 vest equally over three years, with one-third of the shares vesting each year starting from New Employee 1's date of hire.

Jaguar Health Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Magdalena aiming to submit Investigational New Drug (IND) application in early 2025 to the FDA for a next-generation psychoactive prescription drug candidate for potential mental health indications such as ADHD and schizophrenia, with 1-2 additional IND applications filed in 2025 SAN FRANCISCO, CA / ACCESSWIRE / October 10, 2024 / Jaguar Health, Inc. (NASDAQ:JAGX) today announced that Dr. Karen Brunke, Jaguar's EVP of Corporate and Business Development and Acting CEO of Magdalena Biosciences, Inc. (Magdalena), the joint venture recently formed by Jaguar and Filament Health Corp. (OTCQB:FLHLF)(CBOE CA:FH)(FSE:7QS) to develop novel, natural prescription medicines derived from plants for mental health indications, is presenting on Wednesday, October 16, 2024 at 10:15 a.m. PDT at the BIO Investor Forum, which takes place October 15-16 in San Francisco, California.

Magdalena Biosciences, a Joint Venture Between Jaguar Health and Filament Health, to Present October 16 at BIO Investor Forum

SAN FRANCISCO, CA / ACCESSWIRE / October 8, 2024 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar") today announced that a late-breaking abstract evaluating the incidence, severity and management of diarrhea from targeted therapies with or without standard chemotherapy in the cohort of adult patients with breast cancer in the placebo group of the OnTarget phase 3 study recently conducted by Jaguar family company Napo Pharmaceuticals, was submitted by the study's primary investigators to a relevant oncology conference for consideration for a presentation. In this study 142 patients with solid tumors received placebo tablets and nearly 75 of them were patients with breast cancer receiving targeted therapies with or without standard chemotherapy.

Jaguar Health Submits Abstract for First-of-Kind Study Evaluating the Impact of Diarrhea from Cancer Therapies in Breast Cancer Patients Who Received Placebo in its OnTarget Phase 3 Trial

Adult patients with breast cancer are a prespecified subgroup of the recently conducted OnTarget trial evaluating crofelemer for prophylaxis of cancer therapy-related diarrhea OnTarget results in breast cancer patients have been submitted to a relevant oncology conference SAN FRANCISCO, CA / ACCESSWIRE / October 1, 2024 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar") today announced that the recently completed analysis of the prespecified subgroup of adult patients with breast cancer from the company's Phase 3 OnTarget trial indicate that crofelemer achieved statistical significance in this subgroup. Patients with breast cancer accounted for nearly 180 of the 287 participants in this unprecedented prophylactic clinical trial recently conducted by Jaguar family company Napo Pharmaceuticals for diarrhea in adult patients with solid tumors receiving targeted therapy with or without standard chemotherapy.

Jaguar Health Reports Statistically Significant Improvement in Breast Cancer Patients in its Phase 3 OnTarget Trial for its Cancer Supportive Care Drug Crofelemer

Jaguar's commercial focus on cancer supportive care aims to use the best tools and techniques that assess the quality of life of cancer patients and survivors and deliver solutions to address these unmet needs - Commonly used tools and techniques fail to measure what patients are most concerned about Jaguar family company Napo Pharmaceuticals sponsored the "More Than a Diagnosis: A Quality of Life Survey for Individuals with a Diagnosis or History of Cancer" SAN FRANCISCO, CA / ACCESSWIRE / September 26, 2024 / Jaguar Health, Inc. (NASDAQ:JAGX) today announced that Stacey Tinianov, MPH, the founder of Advocates for Collaborative Education (ACE) and a member of Jaguar's Scientific Advisory Board, will conduct a poster presentation on September 27, 2024 at the American Society of Clinical Oncology (ASCO) Quality Care Symposium. The presentation, titled "Measuring what really matters: Advocacy-led co-creation and accrual of a pan-cancer QoL survey," will describe the methodologies and best practices used to design and execute "More Than a Diagnosis: A Quality of Life Survey for Individuals with a Diagnosis or History of Cancer.

Jaguar Health Scientific Advisory Board Member to Share Poster Presentation at American Society of Clinical Oncology (ASCO) Quality Care Symposium About the Methodologies Involved in Designing an Advocate-Led Quality of Life Survey for Cancer Patients and Survivors

SAN FRANCISCO, CA / ACCESSWIRE / September 25, 2024 / Jaguar Health, Inc. (NASDAQ:JAGX) today announced that Lisa Conte, the company's founder, president and CEO, will participate in a webcasted presentation and host one-on-one meetings with investors at the Lytham Partners Fall 2024 Investor Conference , taking place virtually on Tuesday, October 1, 2024. Company Webcast The webcasted presentation will take place at 1:15pm Eastern on Tuesday, October 1, 2024.

Jaguar Health to Participate in the Lytham Partners Fall 2024 Investor Conference on October 1, 2024

Oral mucositis, also called "chemo mouth," has emerged as the most significant adverse event in oncology according to a National Comprehensive Cancer Network task force Up to 40% of all patients treated with chemotherapy develop oral mucositis, and this percentage rises to approximately 90% for patients with head and neck cancers treated with chemotherapy and radiotherapy SAN FRANCISCO, CA / ACCESSWIRE / September 24, 2024 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar") today announced that Jaguar family company Napo Pharmaceuticals (Napo) is exhibiting Gelclair ® , the FDA-approved oral mucositis prescription product, at the American Society for Radiation Oncology (ASTRO) Annual Meeting , which takes place September 29 - October 2, 2024 in Washington, DC. Jaguar plans to begin the U.S. commercial launch in October 2024 for Gelclair.

Jaguar Health to Spotlight Company's Commercial Focus on Cancer Supportive Care at American Society for Radiation Oncology (ASTRO) Annual Meeting for FDA-Approved Gelclair Oral Mucositis Product in Advance of October 2024 Gelclair Launch

SAN FRANCISCO, CA / ACCESSWIRE / September 16, 2024 / Jaguar Health, Inc. (NASDAQ:JAGX) today announced that Lisa Conte, the company's founder, president and CEO, will present in person on September 19, 2024 at the MedInvest Biotech & Pharma Investor Conference and participate in one-on-one meetings at the event, which is taking place September 18-19 in New York City. Participation Instructions for Jaguar Health's Presentation at the MedInvest Biotech & Pharma Investor Conference When: Thursday, September 19, 2024 from 9:55 AM Eastern to 10:10 AM Eastern Registration link for presentation: Click Here About the Jaguar Health Family of Companies Jaguar Health, Inc. (Jaguar) is a commercial stage pharmaceuticals company focused on developing novel proprietary prescription medicines sustainably derived from plants from rainforest areas for people and animals with gastrointestinal distress, specifically associated with overactive bowel, which includes symptoms such as chronic debilitating diarrhea, urgency, bowel incontinence, and cramping pain.

Jaguar Health to Present September 19 at the MedInvest Biotech & Pharma Investor Conference

FDA-approved Gelclair ® is company's third commercialized prescription product Susan Krizancic appointed to role of National Sales Director at Jaguar family company Napo Pharmaceuticals SAN FRANCISCO, CA / ACCESSWIRE / September 10, 2024 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar") today announced that it has appointed biopharmaceutical industry veteran Susan Krizancic to the role of National Sales Director for Jaguar family company Napo Pharmaceuticals. "Sue is a dynamic and proven commercial leader with 30 years of experience in the biopharmaceuticals industry - including 15 years of recent experience in the oncology market - building high-performing teams and exceeding sales targets.

Jaguar Health Appoints Industry Veteran to Head Sales for Company's Commercialized Oncology and HIV Products Including October 2024 Launch of Gelclair for Cancer Supportive Care

SAN FRANCISCO, CA / ACCESSWIRE / September 6, 2024 / Jaguar Health, Inc. (NASDAQ:JAGX) today announced that Lisa Conte, the company's founder, president and CEO, will be presenting virtually, and meeting virtually with investors, at the H.C. Wainwright 26th Annual Global Investment Conference, which takes place September 9-11, 2024.

Jaguar Health to Present at the September 9-11 H.C. Wainwright Annual Global Investment Conference

Company's Canalevia®-CA1 prescription drug is FDA conditionally approved for treatment of chemotherapy-induced diarrhea (CID) in dogs and is the first and only treatment for CID in dogs to receive any type of approval from FDA SAN FRANCISCO, CA / ACCESSWIRE / September 5, 2024 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar") is proud to be celebrating National Service Dog Month, a time devoted to raising awareness and showing appreciation for the extraordinary work service dogs do every day for the people in their care. "September is National Service Dog Month.

Jaguar Health Celebrates National Service Dog Month: With its Supportive Cancer Care Drugs, Jaguar is Dedicated to the Health and Wellbeing of People and Dogs

Click here to view interview video Paramount near-term activities include planned October 2024 commercial launch of FDA-approved oral mucositis prescription product Gelclair ® and results from independent, investigator-initiated trials of crofelemer for rare diseases SAN FRANCISCO, CA / ACCESSWIRE / September 4, 2024 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar") today announced that a new Innovators with Jane King video interview of Lisa Conte, Jaguar's founder, president, and CEO, is available and can be viewed by clicking here . "Our paramount near-term activities are our planned October 2024 commercial launch of the FDA-approved oral mucositis prescription product Gelclair in the U.S. and progressing our rare disease development business," said Conte.

New Innovators with Jane King Interview with Jaguar Health CEO Lisa Conte Spotlights Company's Near-Term Commercial & Development Milestones

New patent issued for core rare disease target indication for crofelemer Napo has approximately 230 patents issued and pending Jaguar is supporting independent investigator-initiated proof-of-concept studies of crofelemer for the rare disease indications of SBS and microvillus inclusion disease (MVID), an ultrarare congenital diarrheal disorder (CDD), in the US, EU, and Middle East/North Africa regions, with results expected by the end of 2024 and throughout 2025 SAN FRANCISCO, CA / ACCESSWIRE / August 27, 2024 / Jaguar Health, Inc. (NASDAQ:JAGX) (Jaguar) today announced that the country of Jordan's Industrial Property Protection Directorate has issued a new patent to Jaguar family company Napo Pharmaceuticals (Napo) for methods for treating short bowel syndrome (SBS), bile acid diarrhea, and diarrhea associated with small intestine resection or gallbladder removal, in patients with an inhibitor of chloride-ion transport such as crofelemer, Jaguar's novel plant-based prescription drug. "We are very pleased that this patent has been issued and believe that it further enhances our intellectual property protection for crofelemer for our core rare disease target indication of SBS," said Lisa Conte, Jaguar's founder, president, and CEO.

Patent Issued in Jordan Bolsters IP Protection for Jaguar Health in the Treatment of Short Bowel Syndrome (SBS)

Magdalena Biosciences, a joint venture formed by Jaguar and Filament Health, is focused on developing novel prescription psychoactive plant-based medicines for various mental health indications SAN FRANCISCO, CA / ACCESSWIRE / August 20, 2024 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar") today announced that Eduardo Zimmer, Ph.D., a key collaborator with Magdalena Biosciences ("Magdalena"), the joint venture formed by Jaguar and Filament Health Corp. (OTCQB:FLHLF)(CBOE CA:FH)(FSE:7QS) to develop novel, natural prescription psychoactive medicines derived from plants for mental health indications, is the 2024 recipient of the prestigious Blas Frangione Early Career Achievement Award.

Key Collaborator of Jaguar Health Joint Venture Magdalena Biosciences Receives Prestigious Alzheimer's Association Award

New patent issued for core rare disease target indication for crofelemer Napo has approximately 230 patents issued and pending Jaguar is supporting independent investigator-initiated proof-of-concept studies of crofelemer for the rare disease indications of SBS and microvillus inclusion disease (MVID), an ultrarare congenital diarrheal disorder (CDD), in the US, EU, and Middle East/North Africa regions, with results expected by the end of 2024 and throughout 2025 SAN FRANCISCO, CA / ACCESSWIRE / August 19, 2024 / Jaguar Health, Inc. (NASDAQ:JAGX) (Jaguar) today announced that Hong Kong's Intellectual Property Department has issued a new patent to Jaguar family company Napo Pharmaceuticals for methods for treating short bowel syndrome (SBS), bile acid diarrhea, and diarrhea associated with small intestine resection or gallbladder removal, in patients with an inhibitor of chloride-ion transport such as crofelemer, Jaguar's novel plant-based prescription drug. "We are very happy that this patent has been issued and believe that it further enhances our intellectual property protection for crofelemer for our core rare disease target indication of SBS," said Lisa Conte, Jaguar's founder, president, and CEO.

Issuance of New Hong Kong Patent Bolsters IP Protection for Jaguar Health in the Treatment of Short Bowel Syndrome (SBS)

Jaguar Health, Inc. (NASDAQ:JAGX ) Q2 2024 Earnings Conference Call August 13, 2024 8:30 AM ET Company Participants Lisa Conte - Founder, President & Chief Executive Officer Pravin Chaturvedi - Chief Scientific Officer Cathy Collis - Senior Vice President of Growth Strategy Carol Lizak - Chief Financial Officer Conference Call Participants Operator [Call starts abruptly] Before I turn the call over to the management, I would like to remind you that the management may make forward-looking statements relating to such matters as continued growth prospects for the company, uncertainties regarding market acceptance of products, the impact of competitive products and pricing, industry trends and productive initiatives, including products in the development stage which may not achieve scientific objectives or meet stringent regulatory requirements. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from those contemplated in such forward-looking statements.

Jaguar Health, Inc. (JAGX) Q2 2024 Earnings Call Transcript

The combined net Q2 2024 revenue of approximately $2.72 million for prescription and non-prescription products increased approximately 16% versus net Q1 2024 revenue of $2.35 million and 2.0% versus net Q2 2023 revenue of $2.67 million Company to complete analysis of full data for first and second 12-week periods of pivotal phase 3 OnTarget trial of crofelemer for prophylaxis of cancer therapy-related diarrhea (CTD) in support of FDA discussion; Jaguar to explore possible approval pathway for crofelemer in breast and lung cancer based on phase 3 results Jaguar planning to begin commercial launch in October 2024 for Gelclair ®, the company's third prescription product Import permit for crofelemer granted for independent, investigator-initiated proof-of-concept trial in Abu Dhabi in pediatric patients for the rare and orphan disease indications of microvillus inclusion disease (MVID) and short bowel syndrome (SBS) with intestinal failure REMINDER: Jaguar to host investor webcast Tuesday, August 13th at 8:30 a.m. Eastern regarding Q2 2024 financials and company updates; Click here to register for webcast SAN FRANCISCO, CA / ACCESSWIRE / August 13, 2024 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") today reported its consolidated second-quarter 2024 financial results and provided Company updates.

News for Jaguar Health Stock (JAGX)